{"id":"motivation-phase-nicotine-mini-lozenge","safety":{"commonSideEffects":[{"rate":null,"effect":"Mouth irritation"},{"rate":null,"effect":"Hiccups"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicotine is a nicotinic acetylcholine receptor agonist that stimulates dopamine release in reward pathways, partially satisfying the brain's dependence on nicotine from cigarettes. By providing controlled nicotine delivery via a lozenge formulation, it reduces the severity of withdrawal symptoms and cravings, facilitating the transition away from smoking. The 'Motivation-Phase' designation suggests this product is intended for use during the active motivation and early cessation phase of smoking cessation therapy.","oneSentence":"Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:58.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation aid for nicotine dependence"}]},"trialDetails":[{"nctId":"NCT06966362","phase":"PHASE4","title":"Varenicline for Smoking Reduction in Veterans Not Ready To Quit","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-07-01","conditions":"Veterans, Tobacco Use Disorder, Cigarette Smoking","enrollment":400},{"nctId":"NCT02973425","phase":"NA","title":"Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2016-11-07","conditions":"Smoking Cessation","enrollment":433}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nicorette"],"phase":"marketed","status":"active","brandName":"Motivation-Phase Nicotine Mini-Lozenge","genericName":"Motivation-Phase Nicotine Mini-Lozenge","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid for individuals motivated to quit smoking.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}